DK1082302T3 - En VLA-4-inhibitor: oMePUPA-V - Google Patents

En VLA-4-inhibitor: oMePUPA-V

Info

Publication number
DK1082302T3
DK1082302T3 DK99926019T DK99926019T DK1082302T3 DK 1082302 T3 DK1082302 T3 DK 1082302T3 DK 99926019 T DK99926019 T DK 99926019T DK 99926019 T DK99926019 T DK 99926019T DK 1082302 T3 DK1082302 T3 DK 1082302T3
Authority
DK
Denmark
Prior art keywords
omepupa
inhibitor
vla
cell
methylphenylamino
Prior art date
Application number
DK99926019T
Other languages
Danish (da)
English (en)
Inventor
Wen-Cherng Lee
Alan Gill
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Application granted granted Critical
Publication of DK1082302T3 publication Critical patent/DK1082302T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK99926019T 1998-05-28 1999-05-28 En VLA-4-inhibitor: oMePUPA-V DK1082302T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8706498P 1998-05-28 1998-05-28
PCT/US1999/011924 WO1999061421A1 (en) 1998-05-28 1999-05-28 A NOVEL VLA-4 INHIBITOR: oMePUPA-V

Publications (1)

Publication Number Publication Date
DK1082302T3 true DK1082302T3 (da) 2004-04-26

Family

ID=22202907

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99926019T DK1082302T3 (da) 1998-05-28 1999-05-28 En VLA-4-inhibitor: oMePUPA-V

Country Status (31)

Country Link
US (1) US6495525B1 (zh)
EP (1) EP1082302B1 (zh)
JP (1) JP2002516309A (zh)
KR (1) KR100636713B1 (zh)
CN (1) CN1148350C (zh)
AT (1) ATE256659T1 (zh)
AU (1) AU764108B2 (zh)
BG (1) BG65021B1 (zh)
CA (1) CA2333656C (zh)
CZ (1) CZ298413B6 (zh)
DE (1) DE69913687T2 (zh)
DK (1) DK1082302T3 (zh)
EA (1) EA002988B1 (zh)
EE (1) EE04639B1 (zh)
ES (1) ES2211096T3 (zh)
HK (1) HK1035726A1 (zh)
HU (1) HUP0102255A3 (zh)
IL (1) IL139967A (zh)
IS (1) IS5737A (zh)
MX (1) MXPA00011774A (zh)
NO (1) NO317990B1 (zh)
NZ (1) NZ509199A (zh)
PL (1) PL198189B1 (zh)
PT (1) PT1082302E (zh)
SI (1) SI1082302T1 (zh)
SK (1) SK285280B6 (zh)
TR (1) TR200100190T2 (zh)
UA (1) UA65623C2 (zh)
WO (1) WO1999061421A1 (zh)
YU (1) YU75500A (zh)
ZA (1) ZA200007300B (zh)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824037T2 (de) * 1997-11-24 2005-06-02 Merck & Co., Inc. Beta-alanin-derivate als zell-adhäsions-inhibitoren
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
EP1113810B1 (en) * 1998-09-14 2008-12-31 Board of Regents, The University of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding
US6525069B1 (en) 1998-12-18 2003-02-25 Bristol-Myers Squibb Pharma Co. N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
US6630503B1 (en) 1999-08-13 2003-10-07 Biogen, Inc. Cell adhesion inhibitors
CZ20022072A3 (cs) 1999-12-28 2003-05-14 Pfizer Products Inc. Nepeptidylové inhibitory VLA-4 dependentní buněčné vazby použitelné pro léčbu zánětlivých, autoimunitních a respiračních onemocnění
ATE524441T1 (de) 2000-12-28 2011-09-15 Daiichi Seiyaku Co Vla-4-inhibitoren
CN1826336B (zh) 2003-07-24 2010-06-02 第一制药株式会社 环己烷羧酸类
US7419666B1 (en) 2004-02-23 2008-09-02 Massachusetts Eye And Ear Infirmary Treatment of ocular disorders
US7196112B2 (en) 2004-07-16 2007-03-27 Biogen Idec Ma Inc. Cell adhesion inhibitors
GT200500321A (es) * 2004-11-09 2006-09-04 Compuestos y composiciones como inhibidores de proteina kinase.
US7685367B2 (en) * 2006-03-08 2010-03-23 Microsoft Corporation Multi-cache cooperation for response output caching
RU2009107030A (ru) * 2006-08-02 2010-09-10 Джензим Корпорейшн (Us) Комбинированная терапия
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
AU2009234253C1 (en) 2008-04-11 2015-05-07 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and conjugates thereof
CN102282168A (zh) 2008-11-18 2011-12-14 梅里麦克制药股份有限公司 人血清白蛋白接头以及其结合物
DK2558499T3 (en) 2010-04-16 2017-07-24 Biogen Ma Inc Anti-VLA-4 antibodies
US20150202287A1 (en) 2012-08-30 2015-07-23 Merrimack Pharmaceuticals, Inc. Combination therapies comprising anti-erbb3 agents
CN112867394B (zh) 2018-06-04 2024-09-13 马萨诸塞州渤健公司 具有降低的效应功能的抗vla-4抗体
CN112969700B (zh) 2018-10-30 2024-08-20 吉利德科学公司 作为α4β7整合素抑制剂的咪唑并吡啶衍生物
EP3873605B1 (en) 2018-10-30 2024-10-23 Gilead Sciences, Inc. Compounds for inhibition of alpha4beta7 integrin
KR20240015737A (ko) 2018-10-30 2024-02-05 길리애드 사이언시즈, 인코포레이티드 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체
AU2019373242B2 (en) 2018-10-30 2023-07-13 Gilead Sciences, Inc. Compounds for inhibition of alpha 4 beta 7 integrin
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1149971B (it) 1979-06-11 1986-12-10 Syntex Inc Derivati nonapeptide e decapeptide dell'ormone che rilascia l'ormone luteinizzante
US4725583A (en) 1985-01-23 1988-02-16 Abbott Laboratories Functionalized peptidylaminoalcohols
US4826815A (en) 1985-05-17 1989-05-02 Abbott Laboratories Renin inhibiting compounds
DK163689A (da) 1988-04-08 1989-10-30 Sandoz Ag Peptidderivater
ATE131471T1 (de) 1989-12-22 1995-12-15 Commw Scient Ind Res Org An fette gebundene aminosäuren, peptide oder deren derivate
CA2043741C (en) 1990-06-07 2003-04-01 Kiyofumi Ishikawa Endothelin antagonistic peptide derivatives
US5192746A (en) 1990-07-09 1993-03-09 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5260277A (en) * 1990-09-10 1993-11-09 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
WO1992008464A1 (en) 1990-11-15 1992-05-29 Tanabe Seiyaku Co. Ltd. Substituted urea and related cell adhesion modulation compounds
EP0519748B1 (en) 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
WO1993008823A1 (en) 1991-11-06 1993-05-13 Tanabe Seiyaku Co., Ltd. Guanidinyl and related cell adhesion modulation compounds
EP0617705B1 (en) 1991-11-22 1997-09-24 Yeda Research And Development Company, Ltd. Non-peptidic surrogates of the arg-gly-asp sequence and pharmaceutical compositions comprising them
WO1993012809A1 (en) 1991-12-24 1993-07-08 Fred Hutchinson Cancer Research Center Competitive inhibition of high-avidity alpha4-beta1 receptor using tripeptide ldv
DE4212304A1 (de) 1992-04-13 1993-10-14 Cassella Ag Asparaginsäurederivate, ihre Herstellung und Verwendung
IL102646A (en) 1992-07-26 1996-05-14 Yeda Res & Dev Non-peptidic surrogates of the ldv sequence and pharmaceutical compositions comprising them
SG52262A1 (en) 1993-01-08 1998-09-28 Tanabe Seiyaku Co Peptide inhibitors of cell adhesion
US5314902A (en) 1993-01-27 1994-05-24 Monsanto Company Urea derivatives useful as platelet aggregation inhibitors
DE4309867A1 (de) 1993-03-26 1994-09-29 Cassella Ag Neue Harnstoffderivate, ihre Herstellung und Verwendung
CA2159192C (en) 1993-04-09 2006-07-25 Keiichi Tanaka Immunomodulator cell adhesion inhibitor, and agent for treating and preventing autoimmune diseases
AU693143B2 (en) 1993-12-06 1998-06-25 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
US5434188A (en) 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
WO1998004247A1 (en) * 1996-07-25 1998-02-05 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
EA002988B1 (ru) 2002-12-26
EE200000698A (et) 2002-06-17
KR100636713B1 (ko) 2006-10-20
BG105060A (en) 2001-08-31
CZ298413B6 (cs) 2007-09-26
NO317990B1 (no) 2005-01-17
HUP0102255A2 (hu) 2001-11-28
IL139967A (en) 2005-11-20
EA200001236A1 (ru) 2001-06-25
ZA200007300B (en) 2002-02-27
IS5737A (is) 2000-11-28
ES2211096T3 (es) 2004-07-01
WO1999061421A1 (en) 1999-12-02
PT1082302E (pt) 2004-04-30
UA65623C2 (en) 2004-04-15
AU764108B2 (en) 2003-08-07
NZ509199A (en) 2003-10-31
KR20010043906A (ko) 2001-05-25
JP2002516309A (ja) 2002-06-04
TR200100190T2 (tr) 2001-05-21
ATE256659T1 (de) 2004-01-15
HK1035726A1 (en) 2001-12-07
NO20006023L (no) 2001-01-17
MXPA00011774A (es) 2002-10-17
PL344440A1 (en) 2001-11-05
EP1082302B1 (en) 2003-12-17
AU4219299A (en) 1999-12-13
HUP0102255A3 (en) 2001-12-28
CZ20004425A3 (en) 2001-05-16
DE69913687T2 (de) 2004-10-07
CA2333656C (en) 2008-07-29
YU75500A (sh) 2002-12-10
EE04639B1 (et) 2006-06-15
SK285280B6 (sk) 2006-10-05
US6495525B1 (en) 2002-12-17
CN1307561A (zh) 2001-08-08
NO20006023D0 (no) 2000-11-28
SK18102000A3 (sk) 2001-07-10
BG65021B1 (bg) 2006-12-29
CA2333656A1 (en) 1999-12-02
IL139967A0 (en) 2002-02-10
DE69913687D1 (de) 2004-01-29
SI1082302T1 (en) 2004-06-30
CN1148350C (zh) 2004-05-05
EP1082302A1 (en) 2001-03-14
PL198189B1 (pl) 2008-06-30

Similar Documents

Publication Publication Date Title
DK1082302T3 (da) En VLA-4-inhibitor: oMePUPA-V
BR9908280A (pt) Inibidores de enzimas de fosfolipase
GEP20063956B (en) Cell adhesion inhibitors
ES2196917T3 (es) Amidas heteroaromaticas como inhibidores del factor xa`.
RO117913B1 (ro) Derivaţi de n-[(amino-(imino)metil)fenil]propil amide substituite, compoziţie farmaceutică care îi conţine şi metodă de tratament
AP1787A (en) Novel perindopril salt and pharmaceutical compositions containing same.
WO2001090138A3 (en) SYNTHESIS OF N-[N-(3,3-DIMETHYLBUTYL)-L-α-ASPARTYL]-L-PHENYLALANINE 1-METHYL ESTER USING OXAZOLIDINONE DERIVATIVES
DE69034070D1 (de) Racemisches Huperzin A
AU2002218311A1 (en) Farnesyl protein transferase inhibitors for the treatment of inflammatory bowel disease
BR0307071A (pt) ésteres hidroxamato do ácido n-(fenil 4-substituìdo)-antranìlico
BR9912010A (pt) Polimorfo de um produto farmacêutico
AU2003271811A1 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
ATE319473T1 (de) Melagatran zur behandlung von entzündungen
NO980296D0 (no) Forbedrede terapeutiske midler
AU3719100A (en) Inhibitors of serine protease activity, methods and compositions for treatment of viral infections
PT1268398E (pt) Novo processo de sintese de esteres da n-[(s)-1-carboxibutil]-(s)-alanina e aplicacao a sintese do perindopril
ES2172182T3 (es) Composiciones farmaceuticas que comprenden cefuroxima axetil.
AU2002341555A1 (en) Levothyroxine pharmaceutical compositions, methods of making and methods of administration
AU3183801A (en) Product comprising a heterotrimeric G protein signal transduction inhibitor associated with anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension
CO5070670A1 (es) Taloproteinasas de arilsulfonamidas y estatinas
BR0001144B1 (pt) Composicão farmacêutica de diclofenaco à base de vitamina-e, papaína e hialuronidase
MY137288A (en) New process for the synthesis of n-[(s)-1-ethoxycarbonylbutyl]-(s)-alanine and application in the synthesis of perindopril
ES2173023A1 (es) Composicion farmaceutica con actividad inmunosupresora
FR2844716B1 (fr) Nouvelles compositions pharmaceutiques destinees notamment a l'hygiene des pieds des diabetiques